UCL Institute for Precision Medicine
Precision Medicine is the next generation of healthcare research that has the potential to provide significant benefits to patients, and affect strategic shifts in the way healthcare is delivered. It uses an individual's genetic profile to guide decisions about the prevention, diagnosis, and treatment of disease. Developing new diagnostic tests and expanding the use of biomarkers enables the identification of the molecular cause of disease, and ultimately supports the development of novel, more precisely targeted treatments.
Precision medicine uses an individual's genetic profile to guide decisions made in regard to the prevention, diagnosis, and treatment of a disease. Developing new diagnostic tests and biomarkers that allow the identification of the molecular cause of a disease, will ultimately support the development of novel more precisely targeted treatments.
The goal of the UCL Institute for Precision Medicine is to accelerate the development of new diagnostics, such as in vivo and in vitro tests, biomarkers an imaging technologies
Clinical trials are the means by which investigational agents, devices, or biologics, such as chemotherapy agents, blood products, or gene therapies are scientifically evaluated in human volunteers for safety and efficacy.
Moving forward, innovative clinical trial designs will be necessary to progress toward a more personalised approach.
Target discovery involves the identification and early validation of disease-modifying targets. Biomarkers play an important role in this process as they can be used to indicate disease progression and can be measured accurately with reproducible results.
Plans in development.
The UCL Institute for Precision Medicine aims to accelerate the development of novel drugs and targeted therapies (antisense oligonucleotide, cell and gene therapies).
Strategic Coordinator, UCL Personalised Medicine Domain
Phone: +44 (0)20 7679 8111